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More than 25 years ago, Nordlund et 
al. reported six patients with spreading 
vitiligo treated with applications of 
monobenzone who subsequently devel-
oped a vesicular dermatitis (Nordlund 
et al., 1985). Interestingly, the eruption 
was restricted to the pigmented areas of 
the skin. Patch tests applied to pigment-
ed and depigmented skin produced 
inflammatory responses only within 
the pigmented areas, indicating that the 
effect depends on the presence of mel-
anocytes. In this issue, van den Boorn 
et al. provide an explanation for this 
puzzling phenomenon (Figure 1).
Application of monobenzone induces 
local depigmentation within 2 weeks, 
extending within a few months, however, 
to nonexposed skin sites. This observation 
indicates that monobenzone-induced 
depigment ation is not only based on 
direct effects on melanocytes but also 
involves a systemic process. Histological 
examination of biopsies obtained from 
monobenzone-treated skin revealed 
CD8+ T-cell infiltrates similar to those 
observed in spontaneous vitiligo or 
melanoma-associated hypopigmentation 
(Hartmann et al., 2008), thereby provid-
ing the first clue that the systemic effect 
probably results from an immunological 
process.
The direct effect of monobenzone 
is attributed to inhibition of tyrosinase 
activity. Indeed, van den Boorn et al. 
(2011, this issue) demonstrated that tyro-
sinase metabolized monobenzone to 
4-benzoxy-1,2-benzoquinone, which in 
turn inactivates tyrosinase by formation 
of quinone hapten binding to tyrosinase 
cysteine residues. Thus, monobenzone 
exposure reduces pigment-cell melano-
genesis without exerting selective toxicity. 
Notably, reactive benzene metabolites 
such as quinones are effective contact 
sensitizers, binding to proteins and form-
ing hapten–carrier complexes that trig-
ger hapten-specific immune responses 
(Ezendam et al., 2003). Consequently, 
van den Boorn et al. investigated the 
effects of mono benzone on the immuno-
genicity of pigmented cells, i.e., melano-
cytes and melanoma cells. Exposure to 
monobenzone induced reactive oxygen 
species exclusively in pigmented cells, 
associated with an increased release 
of tyrosinase- and MART-1-containing 
CD63+ exosomes. Exosomes are known 
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Skin pigmentation depends primar-
ily on the amount and type of melanin 
synthesized by melanocytes located in 
the basal layer of the epidermis and its 
distribution toward the surface of the 
epidermis (Yamaguchi et al., 2007). 
Melanin is synthesized within a spe-
cialized organelle, the melanosome. 
The essential enzyme in its synthesis is 
tyrosinase, a melanosomal membrane 
glycoprotein that catalyzes the initial 
and rate-limiting steps of melano-
genesis. Ultimately, melanin packed 
in melanosomes is transferred from the 
melanocytes to adjacent keratinocytes.
Agents to control skin pigmentation 
are used to address a variety of medical 
conditions, such as acquired hyperpig-
mentation and vitiligo (Hartmann et al., 
2004). Hypopigmenting agents include 
hydroquinone or its monobenzyl ether, 
monobenzone (Solano et al., 2006); the 
drug Benoquin, manufactured by ICN, 
contains 20% monobenzone. 
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to induce specific immunity (Thery et 
al., 2009). Moreover, monobenzone also 
affects antigen processing in pigmented 
cells by (i) induction of polyubiquit-
ination of tyrosinase, thereby enhancing 
its presentation in the major histo-
compatibility complex class I pathway, 
and (ii) formation of melanin-containing 
autophagosomes and autolysosomes. 
This autophagocytic response was found 
to target melanosomal tyrosinase pro-
tein via lysosomal degradation to major 
histo compatibility complex class II 
compartments.
The impact of these monobenzone-
induced processes on the induction of 
cellular immune responses was con-
firmed by a series of cross-presentation 
experiments using immature human den-
dritic cells (DCs) and autologous naive T 
cells. These experiments demon strated 
that, in contrast to unexposed melano-
ma cells, intact monobenzone-exposed 
melanoma cells activated DCs that had 
taken up exosomes from these cells. 
Subsequently, these DCs, cultivated 
with lymphocytes from healthy human 
donors, induced a robust melanoma-
reactive CD8+ T-cell response within 
7 days in vitro. Notably, the induced 
T-cell response was not restricted to 
monobenzone-treated melanoma cells 
(i.e., specific for epitopes linked to 
quinone hapten) because unexposed 
melanoma cells were recognized as 
well. However, the increased exosome 
secretion alone cannot account for the 
observed DC activation by monoben-
zone-exposed melanoma cells. Thus, it 
is important to note that monobenzone-
exposed pigmented cells may activate 
DCs in two ways: (i) DC uptake of qui-
none-haptenated tyrosinase-containing 
exosomes augments DC activation 
via additional triggering of the NALP3 
inflammasome and (ii) the generation of 
reactive oxygen species mediates ATP 
release from exposed cells, stimulating 
activation of the inflammasome in local 
DCs (Schroder and Tschopp, 2010).
The recent advent of ipilimumab in 
the armamentarium for melanoma treat-
ment finally fulfilled the long-cherished 
hope for a successful immunotherapy to 
treat this tumor (Hodi et al., 2010). The 
immunogenicity of melanoma has been 
deduced from T cell–mediated sponta-
neous regressions of primary tumors and 
the occurrence of melanoma-associated 
hypopigmentations (Becker et al., 1999; 
thor Straten et al., 1996). In this regard, 
the present report by van den Boorn et 
al. not only provides the modus operandi 
for the hypopigmenting agent monoben-
zone but also creates the opportunity 
for an innovative, easy-to-use immu-
notherapy for melanoma. Indeed, the 
same researchers recently reported that 
monobenzone cream combined with 
the immunostimulatory adjuvans CpG 
and imiquimod synergistically induce 
potent melanoma antigen-specific 
immunity and tumor eradication in a 
murine model of melanoma (van den 
Boorn et al., 2010). Contact-sensitizing 
compounds generating haptens such as 
Clinical Implications
•  Monobenzone precipitates the development of cellular immunity 
against melanocytes.
•  Current research is directed toward the hypothesis that monobenzone 
will precipitate the development of useful anti-melanoma cellular 
immunity in similar fashon.
•  The search for more effective treatments for melanoma has received 
new impetus. 
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Figure 1. Different effects of monobenzone treatment on pigmented cells. Tyrosinase (Tyr.), the 
rate limiting enzyme in the synthesis of melanin in melanosomes, catalyzes metabolite formation of 
monobenzone. Quinone haptens derived from the metabolite 4-benzoxy-1,2-benzoquinone bind to 
tyrosinase cysteine residues which leads to reduced melanin synthesis (upper left corner). In addition, 
augmented ubiquitination (Ub) of tyrosinase protein by monobenzone exposure enhances the 
presentation of this enzyme by MHC class I (lower left corner). Monobenzone induces reactive oxygen 
species (ROS) exclusively in pigmented cells. These ROS provoke the increased release of tyrosinase 
and Mart-1 containing exosomes and adenosine triphosphate (ATP) as well as melanosome autophagy. 
The autophagocytic response targets melanosomal tyrosinase protein via lysosomal degradation to MHC 
class-II compartments (upper right). Immature dendritic cells will be activated upon endocytosis of 
quinone-haptenated tyrosinase containing exosomes triggering the NALP3 inflammasome. In addition, 
ATP released from monobenzone exposed cells will stimulate activation of the inflammasome (lower 
right). These activated and pigmented cell antigen presenting dendritic cells are then capable of inducing 
a specific immune response (lower middle). MHC, major histocompatibility complex.
commentary
 www.jidonline.org 1187
dinitrochloro benzene have been used 
for melanoma therapy in both preclini-
cal and clinical studies (Terheyden et 
al., 2007; Wack et al., 2002). However, 
as elegantly demonstrated by van 
den Boorn et al. (2011, this issue), 
mono benzone is more specific than 
dinitrochlorobenzene because it is active 
only in pigmented cells. Moreover, it is 
already available as a registered drug 
with a well-established toxicity profile. 
It is hoped the present report by van den 
Boorn et al. will prompt clinical trials 
testing this concept for immunotherapy 
of melanoma.
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Melanoma has now become the subject of targeted therapies, based upon the 
high prevalence of B-raf mutations in melanoma. However, while initial responses 
to B-raf inhibitors are impressive, resistance is extremely common, suggesting that 
melanoma is not addicted to B-raf. In their report, Syed et al. demonstrate that 
fisetin, a natural product without well established mechanisms, has activity against 
melanoma. Their report suggests that "nontargeted therapies" need to become 
part of our armamentarium against melanoma, given that targeted therapies do 
not target all of the pathways required for melanoma growth.
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Several common genetic events in 
melanoma have been elucidated in 
recent years. These include onco-
genic events, such as the B-raf V600E 
mutation, amplification of the micro-
phthalmia transcription factor (MITF), 
and Nras mutations. Common tumor 
suppressor events include inactivation 
of the p16ink4a tumor suppressor gene, 
often by deletion or hyper methylation, 
and loss and/or mutation of PTEN, a 
common event in melanomas with 
B-raf mutations. Melanomas have 
been shown to exhibit differing genetic 
pathways to reach these mutations, 
depending on their anatomic location. 
The pathways involve a complex inter-
play among pigmentation genes such 
as melanocortin 1 receptor, c-kit, and 
DNA repair genes.
As our understanding of melano-
ma genetics has increased, so has our 
understanding of the signaling pathways 
relevant to melanoma progression. The 
current concept of atypical nevi giving 
rise to a non invasive melanoma (radial 
growth phase) and then to an invasive 
and potentially metastatic phenotype 
has been confirmed with distinct sig-
naling events, although melanomas 
may also arise in the absence of pre-
existing nevi. Atypical nevi are clonal 
neoplasms with a high frequency of 
B-raf mutations, but despite the activa-
tion of B-raf, they do not exhibit stable 
activation of MAP kinase (p42/44 ERK). 
Radial growth melanoma demonstrates 
high levels of expression of acti-
vated MAP kinase, as well as of Id-1 
and telomerase. Invasive melanoma 
autophagy. J Invest Dermatol 131:1240–51
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